Tokyo, Japan

Naozumi Samata


Average Co-Inventor Count = 7.2

ph-index = 3

Forward Citations = 67(Granted Patents)


Company Filing History:


Years Active: 1999-2000

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Naozumi Samata: Innovator in Isoxazole Compounds

Introduction

Naozumi Samata is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medicinal chemistry, particularly through his work on isoxazole derivatives. With a total of three patents to his name, Samata's innovations are aimed at addressing critical health issues.

Latest Patents

Samata's latest patents include innovative isoxazole compounds that exhibit excellent monoamine oxidase inhibitory activity. One of his notable inventions is an isoxazole compound designed for the treatment of Parkinson's disease, depression, and Alzheimer's disease. This compound features a specific formula where R.sup.1 can represent various functional groups, and it has shown promising results in therapeutic applications. Another patent focuses on isoxazole compounds that serve as therapeutic agents against nervous diseases, showcasing their potential in preventing and treating conditions such as depression.

Career Highlights

Naozumi Samata is currently associated with Sankyo Company, Limited, where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on the pharmaceutical industry, particularly in the development of treatments for neurological disorders.

Collaborations

Samata has collaborated with notable colleagues, including Koichi Kojima and Junichi Sakai. These partnerships have contributed to the successful development of his innovative compounds.

Conclusion

Naozumi Samata's contributions to the field of medicinal chemistry, particularly through his work on isoxazole derivatives, highlight his role as a key innovator in developing treatments for serious health conditions. His ongoing research promises to make a significant impact on the future of therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…